CMBA
ADCT icon

C.M. Bidwell & Associates’s ADC Therapeutics ADCT Stock Holding History

C.M. Bidwell & Associates’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.2K Buy
+1,119
New +$4.41K ﹤0.01% 344

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

C.M. Bidwell & Associates's ADCT Position: Q1 2026 in Review

C.M. Bidwell & Associates opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 1,119 shares worth $4.2K. The stake represents ﹤0.01% of the portfolio and ranks #344 among its holdings.

118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • C.M. Bidwell & Associates held 1,119 shares of ADC Therapeutics worth $4.2K as of Q1 2026.
  • ADC Therapeutics was a new C.M. Bidwell & Associates position in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #344 holding.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.